Goodwin Procter LLP advised AbSci on the deal. AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The...
AbSci’s $125 Million Crossover Financing
MannKind Corporation’s $230 Million Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. MannKind Corporation (the “Company”) completed its previously announced private offering (the “Offering”) of $200.0 million aggregate...